Prelude Announces Multiple Clinical and Preclinical Poster Presentations at AACR-NCI-EORTC International Conference
14 Oktober 2023 - 6:30PM
Prelude Therapeutics Incorporated (“Prelude”) (Nasdaq: PRLD), a
clinical-stage precision oncology company, announces multiple
clinical and preclinical posters at the AACR-NCI-EORTC
International Conference on Molecular Targets and Cancer
Therapeutics, known as the Triple Meeting, from October 11 -
15, 2023 at the Hynes Convesntion Center in Boston, MA. The
four Prelude poster presentations include data from two ongoing
Phase 1 clinical trials for Prelude’s CDK9 inhibitor, PRT2527, and
CDK4/6 inhibitor, PRT3645, and two preclinical posters for our
SMARCA2 degrader compound, PRT3789.
“This additional data from our solid tumor trial investigating
our potent and selective CDK9 inhibitor, PRT2527, continues to
support a best-in-class safety and target engagement profile for
the molecule. A second Phase 1 clinical trial in patients with
hematological cancers is also underway, with initial data expected
in 1H 2024,” stated Jane Huang, MD, President and Chief
Medical Officer, Prelude Therapeutics.
Dr. Huang added, “We also presented our initial clinical data
with our differentiated brain and tissue penetrant next generation
CDK4/6 inhibitor, PRT3645, demonstrating a generally well-tolerated
safety profile and high target inhibition reaching levels needed
for efficacy in preclinical studies.”
Clinical Poster Presentations:
Title: A Phase 1 Dose-Escalation Study of PRT2527, a
Cyclin-Dependent Kinase 9 (CDK9) Inhibitor, in Adult Patients with
Advanced Solid Tumors: An Updated Analysis
Summary:
- The overall safety profile observed in this study supports
further development of PRT2527 in combination with other targeted
therapies in hematological malignancies.
Title: A Phase 1 Open-Label, Dose-Escalation Study of Central
Nervous System–Penetrant Cyclin-Dependent Kinase (CDK)4/6 Inhibitor
PRT3645 in Patients with Select Advanced or Metastatic Solid
Tumors
Summary
- Initial clinical data from first three dose escalation cohorts
(20, 40 and 80 mg QD) were reported.
- Treatment with PRT3645 was associated with a substantial
decrease in pRb and Ki67 expression, indicating a high level of
target engagement at the doses evaluated.
- PRT3645 exhibited tolerable dose escalation in the initial
three dose cohorts of patients with no significant
gastrointestinal, hematologic or neurological events reported to
date, leveraging its enhanced selectivity profile.
Preclinical Poster Presentations:
“In addition to the preclinical efficacy we have seen with our
potent and selective SMARCA2 degrader, PRT3789, as monotherapy, we
see added potential in combination with immunotherapies as well as
with chemotherapy and targeted therapies, such as KRAS inhibitors.
The sensitive and quantitative assays we have developed to measure
SMARCA2 degradation in preclinical models will also enable us to
assess target engagement in the clinic. We look forward to the
translation of these preclinical results in clinical readouts
planned for 2024,” said Peggy Sherle, Ph.D., Chief Scientific
Officer of Prelude Therapeutics.
Title: Discovery of PRT3789, a First-in-Class Potent and
Selective SMARCA2 Degrader in Clinical Trials for the Treatment of
Patients with SMARCA4 Mutated Cancers
Summary:
- PRT3789 is a potent and highly selective SMARCA2 protein
degrader that specifically targets SMARCA4-deficient cancer
cells.
- In preclinical models, PRT3789 inhibits the growth of
SMARCA4-deficient NSCLC tumors as monotherapy and is synergistic in
combination with other SOC therapies including chemotherapeutic
agents, KRAS G12C inhibitors and anti-PD1 mAb.
Title: Clinical Biomarkers Based on PK/PD Modeling to Guide the
Development for a First-in-Class, Highly Selective SMARCA2 (BRM)
Degrader, PRT3789
Summary:
- Sensitive and quantitative assays to determine SMARCA2 and
SMARCA4 protein levels and changes in SMARCA2-dependent gene
expression were developed and will be used to assess selectivity
and target engagement following treatment with PRT3789 in the
ongoing Phase 1 clinical study.
About Prelude Therapeutics
Prelude Therapeutics is a clinical-stage precision oncology
company developing innovative drug candidates targeting critical
cancer cell pathways. The Company’s diverse pipeline is comprised
of highly differentiated, potentially best-in-class proprietary
small molecule compounds aimed at addressing clinically validated
pathways for cancers with selectable underserved patients.
Prelude’s pipeline includes four candidates currently in clinical
development: PRT1419, a potent, selective inhibitor of MCL1,
PRT2527, a potent and highly selective CDK9 inhibitor, PRT3645 a
next generation CDK4/6 inhibitor, and PRT3789 an
IV administered, potent and highly selective SMARCA2 degrader, and
a preclinical oral candidate targeting SMARCA2.
For more information, visit our website and follow us
on LinkedIn.
Cautionary Note Regarding
Forward-Looking Statements
This press release contains forward-looking
statements within the meaning of the "safe harbor" provisions of
the Private Securities Litigation Reform Act of 1995, including,
but not limited to, anticipated discovery, preclinical and clinical
development activities for Prelude’s product candidates and the
potential benefits of Prelude’s product candidates. All statements
other than statements of historical fact are statements that could
be deemed forward-looking statements. Although Prelude believes
that the expectations reflected in such forward-looking statements
are reasonable, Prelude cannot guarantee future events, results,
actions, levels of activity, performance or achievements, and the
timing and results of biotechnology development and potential
regulatory approval is inherently uncertain. Forward-looking
statements are subject to risks and uncertainties that may cause
Prelude's actual activities or results to differ significantly from
those expressed in any forward-looking statement, including risks
and uncertainties related to Prelude's ability to advance its
product candidates, the receipt and timing of potential regulatory
designations, approvals and commercialization of product
candidates, clinical trial sites and our ability to enroll eligible
patients, supply chain and manufacturing facilities, Prelude’s
ability to maintain and recognize the benefits of certain
designations received by product candidates, the timing and results
of preclinical and clinical trials, Prelude's ability to fund
development activities and achieve development goals, Prelude's
ability to protect intellectual property, and other risks and
uncertainties described under the heading "Risk Factors" in
documents Prelude files from time to time with the Securities and
Exchange Commission. These forward-looking statements speak only as
of the date of this press release, and Prelude undertakes no
obligation to revise or update any forward-looking statements to
reflect events or circumstances after the date hereof.
Investor Contact:Lindsey TrickettVice
President, Investor
Relations240.543.7970ltrickett@preludetx.com
Media Contact:Helen ShikShik Communications
617.510.4373Helen@ShikCommunications.com
Prelude Therapeutics (NASDAQ:PRLD)
Historical Stock Chart
Von Apr 2024 bis Mai 2024
Prelude Therapeutics (NASDAQ:PRLD)
Historical Stock Chart
Von Mai 2023 bis Mai 2024